INVO Fertility, Inc.

INVO Fertility, Inc.

INVO Fertility, Inc. is a publicly traded life sciences company founded to commercialize the INVOcell system, a medical device that enables intravaginal embryo culture as a less expensive alternative to traditional in vitro fertilization. The firm's business model spans device manufacturing, distribution, and the operation of its own INVOclinics that use the technology. The company's strategy combines direct sales of INVOcell consumables to fertility clinics with revenue from its owned clinics, primarily located in the United States and select international markets. INVO Fertility has pursued regulatory clearances and patent protection in multiple countries to expand its commercial footprint. Known partnerships include distribution agreements with fertility centers and healthcare providers in regions such as the Middle East and Latin America. Outside of its core fertility business, INVO Fertility has explored broader women's health applications for its technology platform. The firm's workforce is concentrated in its headquarters and clinical operations, with no disclosed additional offices. Recent public filings indicate continued investment in clinical research and market development, though specific financial disclosures are limited. A key structural differentiator is INVO Fertility's hybrid identity as both a medical device manufacturer and a healthcare services provider, a model that creates potential vertical integration in the fertility treatment value chain. This dual operating structure positions the firm to capture revenue from both device sales and per-cycle treatment fees, a distinction from pure device makers or standalone clinic chains.